Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study

A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omi...

Full description

Saved in:
Bibliographic Details
Published inEClinicalMedicine Vol. 48; p. 101455
Main Authors Auvigne, Vincent, Vaux, Sophie, Strat, Yann Le, Schaeffer, Justine, Fournier, Lucie, Tamandjou, Cynthia, Montagnat, Charline, Coignard, Bruno, Levy-Bruhl, Daniel, Parent du Châtelet, Isabelle
Format Journal Article
LanguageEnglish
Published England Elsevier Ltd 01.06.2022
Elsevier
Subjects
Online AccessGet full text

Cover

Loading…
Abstract A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. Between 06/12/2021–28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08–0·20 among 40–64 years, aHR=0·50 95%CI: 0·26–0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86–6·01 among 40–64 years) and in males (aHR=2·28 95%CI: 1·82–2·85among 40–64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58–9·54 among 40–64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12–0·69). This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. The study was performed as part of routine work at Public Health France.
AbstractList BackgroundA rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. MethodsWe conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. FindingsBetween 06/12/2021-28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08-0·20 among 40-64 years, aHR=0·50 95%CI: 0·26-0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86-6·01 among 40-64 years) and in males (aHR=2·28 95%CI: 1·82-2·85among 40-64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58-9·54 among 40-64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12-0·69). InterpretationThis study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. FundingThe study was performed as part of routine work at Public Health France.
Background: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. Methods: We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. Findings: Between 06/12/2021–28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08–0·20 among 40–64 years, aHR=0·50 95%CI: 0·26–0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86–6·01 among 40–64 years) and in males (aHR=2·28 95%CI: 1·82–2·85among 40–64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58–9·54 among 40–64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12–0·69). Interpretation: This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. Funding: The study was performed as part of routine work at Public Health France.
A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing since July 2021. We aimed to determine whether the risk of a severe hospital event following symptomatic SARS-CoV-2 infection differs for Omicron versus Delta. We conducted a retrospective cohort study to compare severe hospital events (admission to intensive care unit or death) between Omicron and Delta symptomatic cases matched according to week of virological diagnosis and age. The analysis was adjusted for age, sex, vaccination status, presence of comorbidities and region of residence, using Cox proportional hazards model. Between 06/12/2021-28/01/2022, 184 364 cases were included, of which 931 had a severe hospital event (822 Delta, 109 Omicron). The risk of severe event was lower among Omicron versus Delta cases; the difference in severity between the two variants decreased with age (adjusted Hazard Ratio (aHR)=0·13 95%CI: 0·08-0·20 among 40-64 years, aHR=0·50 95%CI: 0·26-0.98 among 80+ years). The risk of severe event increased with the presence of comorbidities (for very-high-risk comorbidity, aHR=4·15 95%CI: 2·86-6·01 among 40-64 years) and in males (aHR=2·28 95%CI: 1·82-2·85among 40-64 years) and was higher in unvaccinated compared to primo-vaccinated (aHR=7·29 95%CI: 5·58-9·54 among 40-64 years). A booster dose reduced the risk of severe hospital event in 80+ years infected with Omicron (aHR=0·29; 95%CI: 0·12-0·69). This study confirms the lower severity of Omicron compared to Delta. However, the difference in disease severity is less marked in the elderly. Further studies are needed to better understand the interactions between age and severity of variants. The study was performed as part of routine work at Public Health France.
ArticleNumber 101455
Author Schaeffer, Justine
Tamandjou, Cynthia
Strat, Yann Le
Auvigne, Vincent
Levy-Bruhl, Daniel
Fournier, Lucie
Montagnat, Charline
Coignard, Bruno
Vaux, Sophie
Parent du Châtelet, Isabelle
Author_xml – sequence: 1
  givenname: Vincent
  orcidid: 0000-0003-3960-3987
  surname: Auvigne
  fullname: Auvigne, Vincent
  email: vincent.auvigne@santepubliquefrance.fr
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 2
  givenname: Sophie
  surname: Vaux
  fullname: Vaux, Sophie
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 3
  givenname: Yann Le
  surname: Strat
  fullname: Strat, Yann Le
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 4
  givenname: Justine
  orcidid: 0000-0003-4311-3294
  surname: Schaeffer
  fullname: Schaeffer, Justine
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 5
  givenname: Lucie
  surname: Fournier
  fullname: Fournier, Lucie
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 6
  givenname: Cynthia
  surname: Tamandjou
  fullname: Tamandjou, Cynthia
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 7
  givenname: Charline
  surname: Montagnat
  fullname: Montagnat, Charline
  organization: Sully Group, 3 av. Doyen Louis Weil, Grenoble 38000 France
– sequence: 8
  givenname: Bruno
  surname: Coignard
  fullname: Coignard, Bruno
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 9
  givenname: Daniel
  surname: Levy-Bruhl
  fullname: Levy-Bruhl, Daniel
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
– sequence: 10
  givenname: Isabelle
  surname: Parent du Châtelet
  fullname: Parent du Châtelet, Isabelle
  organization: Santé publique France, 12 rue du Val d'Osne, Saint-Maurice 94415 France
BackLink https://www.ncbi.nlm.nih.gov/pubmed/35611065$$D View this record in MEDLINE/PubMed
BookMark eNp9Uk1u1DAUjlARLaU3QMhLFs1gO7GTsECqphSKKnXRiq3l2C8zHiV2sJ2pZscduBFH4SQ4TCntho3t9_d9n997L7MD6yxk2WuCFwQT_m6zANUbOywopnR2lYw9y44oq5ucFRU-ePQ-zE5C2GCMKS7rhuMX2WHBOCGYs6Ps5w1swQNauzCaKHuUTBsD6lzfuztjVyjshjG6QUajkLEdqGicRXcmrtGN9CFfuq85RdeDUT75pdXoHPoo0VZ6I2coY9GFl1bBaYooGFrwKMkmv77_-CLtJP1uNul7dIY8RJ-EzBzblD66cerlzJe3MoA-RUmGWoNGyq2djyjESe9eZc872Qc4ub-Ps9uLj7fLz_nV9afL5dlVrkrWxFx3XV3KlqgOF0wDZ7pQUOKq0bjShHDd1rSCVtW6KYFhxbua6XSQGresK4rj7HIPq53ciNGbISkXThrxx-H8SkifmtSD4LRihWa10rQrS87bMnmKQkrNcFEQnrA-7LHGqR1Aq9RyL_snoE8j1qzFym1FQyhpcJUA3t4DePdtghDFYIKCvpcW3BQE5bxJXDWfucp9appPCB66BxqCxbxMYiP2yyTmMYj9MqWyN48lPhT9XZ1_f4DU860BL4IykMasjU8DTF0x_2f4DaSS4ks
CitedBy_id crossref_primary_10_1093_cid_ciad287
crossref_primary_10_3390_ijerph20042987
crossref_primary_10_3390_vaccines10111885
crossref_primary_10_2174_0118715265279242240216114548
crossref_primary_10_1016_j_jiph_2023_05_004
crossref_primary_10_3389_fpubh_2023_1218188
crossref_primary_10_3390_ijerph20042779
crossref_primary_10_1186_s12985_023_02014_1
crossref_primary_10_1017_S0950268823001358
crossref_primary_10_3390_vaccines11121803
crossref_primary_10_1001_jamanetworkopen_2022_27241
crossref_primary_10_3390_jcm12062371
crossref_primary_10_1016_j_jtcme_2024_05_004
crossref_primary_10_3390_microbiolres14020057
crossref_primary_10_1186_s12879_023_08257_1
crossref_primary_10_3389_fimmu_2023_1130539
crossref_primary_10_1001_jamanetworkopen_2023_54991
crossref_primary_10_1016_j_tifs_2022_12_012
crossref_primary_10_1080_21645515_2023_2167410
crossref_primary_10_1186_s12879_023_08714_x
crossref_primary_10_1136_bmjgh_2023_012328
crossref_primary_10_1016_j_cmi_2022_12_020
crossref_primary_10_1093_eurjpc_zwac228
crossref_primary_10_1371_journal_pgph_0001896
crossref_primary_10_3389_fmicb_2023_1051104
crossref_primary_10_1007_s11845_022_03266_6
crossref_primary_10_1093_ofid_ofac406
crossref_primary_10_1038_s41598_023_48272_5
crossref_primary_10_1080_21645515_2023_2212568
crossref_primary_10_1016_j_vaccine_2023_02_062
crossref_primary_10_1177_14034948221108548
crossref_primary_10_1097_MD_0000000000033024
crossref_primary_10_1038_s41598_023_41060_1
crossref_primary_10_1093_cid_ciac933
crossref_primary_10_1136_bmjopen_2023_076892
Cites_doi 10.1186/s13293-020-00304-9
10.1016/j.ijid.2021.12.357
10.1038/s41586-022-04465-y
10.1016/S0140-6736(22)00462-7
10.1038/s41586-022-04441-6
10.1056/NEJMc2200133
10.3389/fpubh.2020.00152
10.1038/d41586-021-03552-w
10.1001/jama.2021.24868
10.1038/nri2318
10.2139/ssrn.3996320
10.2807/1560-7917.ES.2022.27.4.2200077
10.1056/NEJMc2119270
10.2807/1560-7917.ES.2022.27.13.2200247
10.15585/mmwr.mm6924e2
10.1126/sciimmunol.abo2202
10.1038/s41586-022-04460-3
10.1038/s41586-022-04479-6
ContentType Journal Article
Copyright 2022 The Author(s)
2022 The Author(s).
2022 The Author(s) 2022
Copyright_xml – notice: 2022 The Author(s)
– notice: 2022 The Author(s).
– notice: 2022 The Author(s) 2022
DBID 6I.
AAFTH
NPM
AAYXX
CITATION
7X8
5PM
DOA
DOI 10.1016/j.eclinm.2022.101455
DatabaseName ScienceDirect Open Access Titles
Elsevier:ScienceDirect:Open Access
PubMed
CrossRef
MEDLINE - Academic
PubMed Central (Full Participant titles)
DOAJ Directory of Open Access Journals
DatabaseTitle PubMed
CrossRef
MEDLINE - Academic
DatabaseTitleList MEDLINE - Academic

PubMed

Database_xml – sequence: 1
  dbid: DOA
  name: Directory of Open Access Journals (DOAJ)
  url: https://www.doaj.org/
  sourceTypes: Open Website
– sequence: 2
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
EISSN 2589-5370
EndPage 101455
ExternalDocumentID oai_doaj_org_article_62753d58cd2f4466b462733aad503316
10_1016_j_eclinm_2022_101455
35611065
S2589537022001857
Genre Journal Article
GroupedDBID .1-
.FO
0SF
53G
6I.
AACTN
AAEDW
AAFTH
AALRI
AAXUO
ABMAC
ACLIJ
ADBBV
AEXQZ
AFCTW
AFRHN
AFTJW
AITUG
AJUYK
ALMA_UNASSIGNED_HOLDINGS
AMRAJ
AOIJS
BCNDV
EBS
EJD
FDB
GROUPED_DOAJ
HYE
M41
NCXOZ
OK1
ROL
RPM
SSZ
Z5R
0R~
AAMRU
ADVLN
NPM
AAYXX
CITATION
7X8
5PM
ID FETCH-LOGICAL-c459t-dff84ab1cf035de65d3ce4079d07d116db827ebc8d94e50c6f85d6f8180b5f33
IEDL.DBID RPM
ISSN 2589-5370
IngestDate Tue Oct 22 15:12:32 EDT 2024
Tue Sep 17 21:14:54 EDT 2024
Wed Jul 24 17:12:30 EDT 2024
Thu Sep 26 19:36:25 EDT 2024
Sat Sep 28 08:19:14 EDT 2024
Tue Jul 25 20:59:41 EDT 2023
IsDoiOpenAccess true
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Keywords COVID-19
SARS-CoV-2
Omicron
Delta
Epidemiology
Vaccination
Language English
License This is an open access article under the CC BY-NC-ND license.
2022 The Author(s).
This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
LinkModel DirectLink
MergedId FETCHMERGED-LOGICAL-c459t-dff84ab1cf035de65d3ce4079d07d116db827ebc8d94e50c6f85d6f8180b5f33
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ORCID 0000-0003-4311-3294
0000-0003-3960-3987
OpenAccessLink https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9121907/
PMID 35611065
PQID 2669503866
PQPubID 23479
PageCount 1
ParticipantIDs doaj_primary_oai_doaj_org_article_62753d58cd2f4466b462733aad503316
pubmedcentral_primary_oai_pubmedcentral_nih_gov_9121907
proquest_miscellaneous_2669503866
crossref_primary_10_1016_j_eclinm_2022_101455
pubmed_primary_35611065
elsevier_sciencedirect_doi_10_1016_j_eclinm_2022_101455
PublicationCentury 2000
PublicationDate 2022-06-01
PublicationDateYYYYMMDD 2022-06-01
PublicationDate_xml – month: 06
  year: 2022
  text: 2022-06-01
  day: 01
PublicationDecade 2020
PublicationPlace England
PublicationPlace_xml – name: England
PublicationTitle EClinicalMedicine
PublicationTitleAlternate EClinicalMedicine
PublicationYear 2022
Publisher Elsevier Ltd
Elsevier
Publisher_xml – name: Elsevier Ltd
– name: Elsevier
References Keeton, Tincho, Ngomti (bib0022) 2022; 603
Sante publique France. Risk analysis on emerging variants of SARS-CoV-2 carried out jointly by Public Health France and the CNR for respiratory infection viruses update of 05/01/2022. 2022
Jassat, Karim, Mudara (bib0007) 2021
Veneti, Bøås, Bråthen Kristoffersen (bib0017) 2022; 27
Nikolich-Zugich (bib0027) 2008; 8
Bastard, Taisne, Figoni (bib0031) 2022; 27
Ministère des solidarités et de la Santé. Le Gouvernement ouvre la vaccination aux patients vulnérables à très haut risque à compter du 18 janvier - Ministère des Solidarités et de la Santé (solidarites-sante.gouv.fr). 2022
Bentley, Kirby, Sharma, Kipar, Mega, Bramwell (bib0023) 2021
Sante publique France. COVID-19: epidemiological update. Weekly report. Week 1. 13 January 2022. 2022
Altarawneh, Chemaitelly, Hasan (bib0032) 2022; 386
Jin, Bai, He (bib0030) 2020; 8
Callaway (bib0001) 2021; 600
Lu, Mok, Chen (bib0018) 2021
Lefrancq, Paireau, Hoze (bib0012) 2021; 5
Wolter, Jassat, Walaza, Welch, Moultrie, Groome (bib0013) 2021
Abdullah, Myers, Basu (bib0006) 2021; 116
Nyberg, Ferguson, Nash (bib0016) 2022; 399
Maslo, Friedland, Toubkin, Laubscher, Akaloo, Kama (bib0008) 2021; 327
Stokes, Zambrano, Anderson (bib0028) 2020; 69
Davies, Kassanjee, Rousseau, Morden, Johnson, Solomon (bib0009) 2022; Online ahead of print
Liu, Chandrashekar, Sellers, Barrett, Jacob-Dolan, Lifton (bib0021) 2022; 603
Lewnard, Hong, Patel, Kahn, Lipsitch, Tartof (bib0015) 2022
Madhi, Kwatra, Myers, Jassat, Dhar, Mukendi (bib0005) 2022
.
Hui, Ho, Cheung (bib0025) 2022; 603
Gebhard, Regitz-Zagrosek, Neuhauser, Morgan, Klein (bib0029) 2020; 11
Ulloa, Buchan, Daneman, Brown (bib0014) 2022
Accessed 5 May 2022.
Accessed 5 May 2022
Collie, Champion, Moultrie, Bekker, Gray (bib0019) 2021; 386
GeurtsvanKessel, Geers, Schmitz (bib0020) 2022; 7
(bib0002) 2022
Halfmann, Iida, Iwatsuki-Horimoto, Maemura, Kiso, Scheaffer (bib0024) 2022; 603
Jassat (10.1016/j.eclinm.2022.101455_bib0007) 2021
Lefrancq (10.1016/j.eclinm.2022.101455_bib0012) 2021; 5
Collie (10.1016/j.eclinm.2022.101455_bib0019) 2021; 386
10.1016/j.eclinm.2022.101455_bib0003
Hui (10.1016/j.eclinm.2022.101455_bib0025) 2022; 603
Bentley (10.1016/j.eclinm.2022.101455_bib0023) 2021
GeurtsvanKessel (10.1016/j.eclinm.2022.101455_bib0020) 2022; 7
10.1016/j.eclinm.2022.101455_bib0004
Ulloa (10.1016/j.eclinm.2022.101455_bib0014) 2022
Nyberg (10.1016/j.eclinm.2022.101455_bib0016) 2022; 399
Bastard (10.1016/j.eclinm.2022.101455_bib0031) 2022; 27
Maslo (10.1016/j.eclinm.2022.101455_bib0008) 2021; 327
Jin (10.1016/j.eclinm.2022.101455_bib0030) 2020; 8
Wolter (10.1016/j.eclinm.2022.101455_bib0013) 2021
Liu (10.1016/j.eclinm.2022.101455_bib0021) 2022; 603
Nikolich-Zugich (10.1016/j.eclinm.2022.101455_bib0027) 2008; 8
Halfmann (10.1016/j.eclinm.2022.101455_bib0024) 2022; 603
Callaway (10.1016/j.eclinm.2022.101455_bib0001) 2021; 600
Abdullah (10.1016/j.eclinm.2022.101455_bib0006) 2021; 116
Davies (10.1016/j.eclinm.2022.101455_bib0009) 2022; Online ahead of print
10.1016/j.eclinm.2022.101455_bib0010
Lewnard (10.1016/j.eclinm.2022.101455_bib0015) 2022
Lu (10.1016/j.eclinm.2022.101455_bib0018) 2021
Madhi (10.1016/j.eclinm.2022.101455_bib0005) 2022
Keeton (10.1016/j.eclinm.2022.101455_bib0022) 2022; 603
Altarawneh (10.1016/j.eclinm.2022.101455_bib0032) 2022; 386
Gebhard (10.1016/j.eclinm.2022.101455_bib0029) 2020; 11
Veneti (10.1016/j.eclinm.2022.101455_bib0017) 2022; 27
Stokes (10.1016/j.eclinm.2022.101455_bib0028) 2020; 69
(10.1016/j.eclinm.2022.101455_bib0002) 2022
References_xml – volume: 600
  start-page: 21
  year: 2021
  ident: bib0001
  article-title: Heavily mutated Omicron variant puts scientists on alert
  publication-title: Nature
  contributor:
    fullname: Callaway
– volume: 69
  start-page: 759
  year: 2020
  end-page: 765
  ident: bib0028
  article-title: Coronavirus disease 2019 case surveillance-United States, January 22–May 30, 2020
  publication-title: MMWR Morb Mortal Wkly Rep
  contributor:
    fullname: Anderson
– volume: 116
  start-page: 38
  year: 2021
  end-page: 42
  ident: bib0006
  article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa
  publication-title: Int J Infect Dis
  contributor:
    fullname: Basu
– volume: 8
  start-page: 152
  year: 2020
  ident: bib0030
  article-title: Gender differences in patients with COVID-19: focus on severity and mortality
  publication-title: Front Public Health
  contributor:
    fullname: He
– volume: 327
  start-page: 583
  year: 2021
  end-page: 584
  ident: bib0008
  article-title: Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves
  publication-title: JAMA
  contributor:
    fullname: Kama
– volume: 27
  year: 2022
  ident: bib0017
  article-title: Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
  publication-title: Eurosurveillance
  contributor:
    fullname: Bråthen Kristoffersen
– year: 2022
  ident: bib0005
  article-title: South African Population Immunity and Severe Covid-19 with Omicron Variant
  publication-title: medRxiv [preprint]
  contributor:
    fullname: Mukendi
– year: 2021
  ident: bib0007
  article-title: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicrondominant fourth wave
  publication-title: SSRN [preprint]
  contributor:
    fullname: Mudara
– volume: 399
  start-page: 1303
  year: 2022
  end-page: 1312
  ident: bib0016
  article-title: Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
  publication-title: Lancet
  contributor:
    fullname: Nash
– volume: 8
  start-page: 512
  year: 2008
  end-page: 522
  ident: bib0027
  article-title: Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections
  publication-title: Nat Rev Immunol
  contributor:
    fullname: Nikolich-Zugich
– volume: 5
  year: 2021
  ident: bib0012
  article-title: Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: a retrospective national surveillance data analysis
  publication-title: Lancet Reg Health Eur
  contributor:
    fullname: Hoze
– volume: 7
  start-page: eabo2202
  year: 2022
  ident: bib0020
  article-title: Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  publication-title: Sci Immunol
  contributor:
    fullname: Schmitz
– year: 2021
  ident: bib0023
  article-title: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
  publication-title: BioRxiv [preprint]
  contributor:
    fullname: Bramwell
– year: 2022
  ident: bib0015
  article-title: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
  publication-title: medRxiv [preprint]
  contributor:
    fullname: Tartof
– volume: 603
  start-page: 493
  year: 2022
  end-page: 496
  ident: bib0021
  article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
  publication-title: Nature
  contributor:
    fullname: Lifton
– volume: 603
  start-page: 488
  year: 2022
  end-page: 492
  ident: bib0022
  article-title: T cell responses to SARS-CoV-2 spike cross-recognize Omicron
  publication-title: Nature
  contributor:
    fullname: Ngomti
– volume: 603
  start-page: 687
  year: 2022
  end-page: 692
  ident: bib0024
  article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
  publication-title: Nature
  contributor:
    fullname: Scheaffer
– volume: Online ahead of print
  year: 2022
  ident: bib0009
  article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa
  publication-title: Tropical Medicine & International Health
  contributor:
    fullname: Solomon
– year: 2022
  ident: bib0002
  article-title: Weekly epidemiological update on COVID-19 - 25 January 2022. Edition 76
– year: 2021
  ident: bib0018
  article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
  publication-title: Clin Infect Dis
  contributor:
    fullname: Chen
– year: 2022
  ident: bib0014
  article-title: Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada
  publication-title: medRxiv [preprint]
  contributor:
    fullname: Brown
– volume: 603
  start-page: 715
  year: 2022
  end-page: 720
  ident: bib0025
  article-title: SARS-CoV-2 Omicron variant replication in human bronchus and lung
  publication-title: Nature
  contributor:
    fullname: Cheung
– year: 2021
  ident: bib0013
  article-title: Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
  publication-title: medRXiv [preprint]
  contributor:
    fullname: Groome
– volume: 386
  start-page: 1288
  year: 2022
  end-page: 1290
  ident: bib0032
  article-title: Protection against the Omicron variant from previous SARS-CoV-2 infection
  publication-title: N Engl J Med
  contributor:
    fullname: Hasan
– volume: 11
  start-page: 29
  year: 2020
  ident: bib0029
  article-title: Impact of sex and gender on COVID-19 outcomes in Europe
  publication-title: Biol Sex Differ
  contributor:
    fullname: Klein
– volume: 27
  year: 2022
  ident: bib0031
  article-title: Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022
  publication-title: Eurosurveillance
  contributor:
    fullname: Figoni
– volume: 386
  start-page: 494
  year: 2021
  end-page: 496
  ident: bib0019
  article-title: Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
  publication-title: N Engl J Med
  contributor:
    fullname: Gray
– volume: 11
  start-page: 29
  issue: 1
  year: 2020
  ident: 10.1016/j.eclinm.2022.101455_bib0029
  article-title: Impact of sex and gender on COVID-19 outcomes in Europe
  publication-title: Biol Sex Differ
  doi: 10.1186/s13293-020-00304-9
  contributor:
    fullname: Gebhard
– volume: 116
  start-page: 38
  year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0006
  article-title: Decreased severity of disease during the first global omicron variant covid-19 outbreak in a large hospital in tshwane, south africa
  publication-title: Int J Infect Dis
  doi: 10.1016/j.ijid.2021.12.357
  contributor:
    fullname: Abdullah
– volume: 603
  start-page: 493
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0021
  article-title: Vaccines elicit highly conserved cellular immunity to SARS-CoV-2 Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04465-y
  contributor:
    fullname: Liu
– volume: 399
  start-page: 1303
  issue: 10332
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0016
  article-title: Comparative analysis of the risks of hospitalisation and death associated with SARS-CoV-2 omicron (B.1.1.529) and delta (B.1.617.2) variants in England: a cohort study
  publication-title: Lancet
  doi: 10.1016/S0140-6736(22)00462-7
  contributor:
    fullname: Nyberg
– year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0015
  article-title: Clinical outcomes among patients infected with Omicron (B.1.1.529) SARS-CoV-2 variant in southern California
  publication-title: medRxiv [preprint]
  contributor:
    fullname: Lewnard
– volume: 603
  start-page: 687
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0024
  article-title: SARS-CoV-2 Omicron virus causes attenuated disease in mice and hamsters
  publication-title: Nature
  doi: 10.1038/s41586-022-04441-6
  contributor:
    fullname: Halfmann
– volume: 386
  start-page: 1288
  issue: 13
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0032
  article-title: Protection against the Omicron variant from previous SARS-CoV-2 infection
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2200133
  contributor:
    fullname: Altarawneh
– volume: 8
  start-page: 152
  year: 2020
  ident: 10.1016/j.eclinm.2022.101455_bib0030
  article-title: Gender differences in patients with COVID-19: focus on severity and mortality
  publication-title: Front Public Health
  doi: 10.3389/fpubh.2020.00152
  contributor:
    fullname: Jin
– ident: 10.1016/j.eclinm.2022.101455_bib0003
– volume: 600
  start-page: 21
  issue: 7887
  year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0001
  article-title: Heavily mutated Omicron variant puts scientists on alert
  publication-title: Nature
  doi: 10.1038/d41586-021-03552-w
  contributor:
    fullname: Callaway
– volume: 327
  start-page: 583
  year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0008
  article-title: Characteristics and outcomes of hospitalized patients in South Africa during the COVID-19 Omicron wave compared with previous waves
  publication-title: JAMA
  doi: 10.1001/jama.2021.24868
  contributor:
    fullname: Maslo
– year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0013
  article-title: Early assessment of the clinical severity of the SARS-CoV-2 Omicron variant in South Africa
  publication-title: medRXiv [preprint]
  contributor:
    fullname: Wolter
– year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0014
  article-title: Early estimates of SARS-CoV-2 Omicron variant severity based on a matched cohort study, Ontario, Canada
  publication-title: medRxiv [preprint]
  contributor:
    fullname: Ulloa
– volume: 8
  start-page: 512
  issue: 7
  year: 2008
  ident: 10.1016/j.eclinm.2022.101455_bib0027
  article-title: Ageing and life-long maintenance of T-cell subsets in the face of latent persistent infections
  publication-title: Nat Rev Immunol
  doi: 10.1038/nri2318
  contributor:
    fullname: Nikolich-Zugich
– volume: 5
  year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0012
  article-title: Evolution of outcomes for patients hospitalised during the first 9 months of the SARS-CoV-2 pandemic in France: a retrospective national surveillance data analysis
  publication-title: Lancet Reg Health Eur
  contributor:
    fullname: Lefrancq
– year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0007
  article-title: Clinical severity of COVID-19 patients admitted to hospitals in Gauteng, South Africa during the Omicrondominant fourth wave
  publication-title: SSRN [preprint]
  doi: 10.2139/ssrn.3996320
  contributor:
    fullname: Jassat
– volume: Online ahead of print
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0009
  article-title: Outcomes of laboratory-confirmed SARS-CoV-2 infection in the Omicron-driven fourth wave compared with previous waves in the Western Cape Province, South Africa
  publication-title: Tropical Medicine & International Health
  contributor:
    fullname: Davies
– year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0002
– ident: 10.1016/j.eclinm.2022.101455_bib0004
– volume: 27
  issue: 4
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0017
  article-title: Reduced risk of hospitalisation among reported COVID-19 cases infected with the SARS-CoV-2 Omicron BA.1 variant compared with the Delta variant, Norway, December 2021 to January 2022
  publication-title: Eurosurveillance
  doi: 10.2807/1560-7917.ES.2022.27.4.2200077
  contributor:
    fullname: Veneti
– year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0018
  article-title: Neutralization of SARS-CoV-2 Omicron variant by sera from BNT162b2 or Coronavac vaccine recipients
  publication-title: Clin Infect Dis
  contributor:
    fullname: Lu
– volume: 386
  start-page: 494
  year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0019
  article-title: Effectiveness of BNT162b2 Vaccine against Omicron Variant in South Africa
  publication-title: N Engl J Med
  doi: 10.1056/NEJMc2119270
  contributor:
    fullname: Collie
– year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0005
  article-title: South African Population Immunity and Severe Covid-19 with Omicron Variant
  publication-title: medRxiv [preprint]
  contributor:
    fullname: Madhi
– volume: 27
  issue: 13
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0031
  article-title: Impact of the Omicron variant on SARS-CoV-2 reinfections in France, March 2021 to February 2022
  publication-title: Eurosurveillance
  doi: 10.2807/1560-7917.ES.2022.27.13.2200247
  contributor:
    fullname: Bastard
– volume: 69
  start-page: 759
  issue: 24
  year: 2020
  ident: 10.1016/j.eclinm.2022.101455_bib0028
  article-title: Coronavirus disease 2019 case surveillance-United States, January 22–May 30, 2020
  publication-title: MMWR Morb Mortal Wkly Rep
  doi: 10.15585/mmwr.mm6924e2
  contributor:
    fullname: Stokes
– volume: 7
  start-page: eabo2202
  issue: 69
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0020
  article-title: Divergent SARS CoV-2 Omicron-reactive T- and B cell responses in COVID-19 vaccine recipients
  publication-title: Sci Immunol
  doi: 10.1126/sciimmunol.abo2202
  contributor:
    fullname: GeurtsvanKessel
– year: 2021
  ident: 10.1016/j.eclinm.2022.101455_bib0023
  article-title: SARS-CoV-2 Omicron-B.1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains in a mouse model of severe COVID-19
  publication-title: BioRxiv [preprint]
  contributor:
    fullname: Bentley
– ident: 10.1016/j.eclinm.2022.101455_bib0010
– volume: 603
  start-page: 488
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0022
  article-title: T cell responses to SARS-CoV-2 spike cross-recognize Omicron
  publication-title: Nature
  doi: 10.1038/s41586-022-04460-3
  contributor:
    fullname: Keeton
– volume: 603
  start-page: 715
  year: 2022
  ident: 10.1016/j.eclinm.2022.101455_bib0025
  article-title: SARS-CoV-2 Omicron variant replication in human bronchus and lung ex vivo
  publication-title: Nature
  doi: 10.1038/s41586-022-04479-6
  contributor:
    fullname: Hui
SSID ssj0002048960
Score 2.4073918
Snippet A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was prevailing...
BackgroundA rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was...
Background: A rapid increase in incidence of the SARS-CoV-2 Omicron variant (sub-lineage BA.1) occurred in France in December 2021, while the Delta variant was...
SourceID doaj
pubmedcentral
proquest
crossref
pubmed
elsevier
SourceType Open Website
Open Access Repository
Aggregation Database
Index Database
Publisher
StartPage 101455
SubjectTerms COVID-19
Delta
Epidemiology
Omicron
SARS-CoV-2
Vaccination
SummonAdditionalLinks – databaseName: DOAJ Directory of Open Access Journals
  dbid: DOA
  link: http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwrV1Lb9RADB6hHhAXxJvlJSNx3IEkM5NMuJVCVVUqHFpQb1EyD7UVTVa7aave-A_8I34KvwR7Jllt4NALl5XyHq-_rO21_ZmxN86XRZKbhBNVCJeNzbk2heL4i9joss51E3gLDj7ne1_l_rE63hj1RTVhkR44fnHviEVXWKWNzTzlHhuJe4Soa0sJuDSSbadqI5g6C-k1qcvQIpwpXdJCkrFvLhR3Oeo7pEb0LHsbptWqiV0K9P0T8_Sv-_l3FeWGWdq9x-4O_iRsRznus1uufcBuHwwZ84fs16FDsDo4GeaDQGBsWoFH_XdXaLdgdX2-6LvA3ApjaVYL9P8sHGLUy3e6bzyDL-dUuddC3Vr46L73NVxilE1FNHgRhPEcbo5HjKMJI4Aip79__NyvW4TgNW1m72Eblq5fdmNz5xwW6-lhnKypnQMuA1Fkgeb2LnsI5LeP2NHup6OdPT7MbeBGqrLn1nst6yY1PhHKulxZYRwGjqVNCpumuW10VrjGaFtKpxKTe60sfqQ6aZQX4jHbarvWPWWgSyOkyrxwhZQuFbq2Aj0k6RIvNXpyM8ZHpVWLyM5RjWVrZ1VUckUiVlHJM_aBNLs-l7i1ww5EXDUgrroJcTNWjLioBjcluh94q9MbHv96hFGFbzGlZurWdRerCt2kkoh5crz7kwir9SIFurgYuOPVxQRwEymmR9rTk8AUXqZokJLi2f8Q-zm7Q6LEMrkXbKtfXriX6JD1zavw7v0BVnMy_w
  priority: 102
  providerName: Directory of Open Access Journals
Title Severe hospital events following symptomatic infection with Sars-CoV-2 Omicron and Delta variants in France, December 2021–January 2022: A retrospective, population-based, matched cohort study
URI https://dx.doi.org/10.1016/j.eclinm.2022.101455
https://www.ncbi.nlm.nih.gov/pubmed/35611065
https://search.proquest.com/docview/2669503866
https://pubmed.ncbi.nlm.nih.gov/PMC9121907
https://doaj.org/article/62753d58cd2f4466b462733aad503316
Volume 48
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3NbtNAEF61PSAuiH_CTzVIHLOJ7d2119xKoKoqBZBaUG-WvT80VWNHjgvqjXfgjXgUnoTZtTdq4IDEJVLs2N7VzGRmPN98Q8grY_MsSlVEHVUI5ZVOqVSZoPiPWMm8TGXleQvm79OjT_z4TJztEBF6YTxoX1WLSX25nNSLc4-tXC3VNODEph_nszxGO4uy6S7ZzRi7kaJf-MoalxiWhzY5j-Uyrs3Q9Z0nycQPp3UDaxiGDpgQiS2P5In7txzT34Hnn_jJGw7p8C65M0SScNCv-B7ZMfV9cms-1MofkJ8nBtXUwPkwGQQ8V9MaLEq--YYeC9bXy1XXeM5WCKCsGtybWTjBfJfOms80gQ9Lh9mroaw1vDWXXQlfMb928Bm8CPxgDjPGM8q42SKAu49_ff9xXNaofNfua_IaDqA1XduEts4xrDZzw6jzo3oMuAzUHw1uYm_bgae9fUhOD9-dzo7oMLGBKi7yjmprJS-rWNmICW1SoZkymDLmOsp0HKe6kklmKiV1zo2IVGql0PgRy6gSlrFHZK9uavOEgMwV4yKxzGScm5jJUjOMjbiJLJcYw40IDUIrVj0vRxEAaxdFL-_CbbHo5T0ib5xkN791rNr-QNN-KQbdKhxjM9NCKp1YV-euOB5hrCy1K_bG6YhkQS-KIUDpAw-81eIfj38Z1KhA-3VFmbI2zdW6wAApd5Q8Kd79ca9Wm0UGDcXnbinc1i62z6DJeI7wwUSe_veVz8htt_4eFfec7HXtlXmB8VdX7fv3Fvve6n4DMikz7Q
link.rule.ids 230,315,733,786,790,870,891,2115,27955,27956,53825,53827
linkProvider National Library of Medicine
linkToHtml http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB2VIgEb3tDwHCSWmcT2zNhjdiVQhdIUpIaqu5HnYZq2saPEAZUV_8Af8Sl8CXfGdtSUBYJNJHv8uskZ33sz556L0Eubp0kQ64A4qRDClImJ0Akn8EZUIs1iobxuwWg_Hn5iu0f8aAPxthbGk_a1mvSKs2mvmBx7buVsqvstT6z_cTRIQ5hnQdK_gq7CfI34hST9xK-tMQGBeVso59lc1hUausrzKOr59rSuZQ2F4AFSIr7mk7x0_5pr-jP0vMygvOCSdm6hw9aYmoly2ltWqqe_XdJ5_Gdrb6ObTZCKt-vhO2jDFnfRtVGzDH8P_TywMAMsPm6ajmAvA7XAOYCq_ArOEC_Op7Oq9HKwuOV7Fdj96YsPIJUmg_KQRPjD1NEBC5wVBr-xZ1WGv0Dq7pg5cBL2PT9sF0a0dW1LMHyt4a_vP3azAnB97jajV3gbz201L9uK0S6erVqSEeeiTRfDYwA0DXbNgOcV9oq699F45-14MCRNMwiiGU8rYvJcsEyFOg8oNzbmhmoL2WhqgsSEYWyUiBKrtDApszzQcS64gY9QBIrnlD5Am0VZ2C2ERaop41FObcKYDanIDIWwi9kgZwLCww4iLRrkrJb8kC0X7kTWQJLORFkDqYNeO8isjnWC3X5HOf8smx9SOjFoarjQJsrdErpisIfSLDNuHTmMOyhpASeb2KeOaeBSk7_c_kWLTwmvBrfekxW2XC4kxF6pU_uJ4eoPa7yuHrKFPtx3DclrVqyPAD69_HiDx0f_feZzdH04Hu3JvXf77x-jG86Wmnz3BG1W86V9CmFepZ75Sf0bALtU6w
linkToPdf http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3LbtNAFB1BkSo2vB8pr0FimUlsz9gesyspUSmkVGpBFZuR50XTNnaUOKCy4h_4Iz6FL-HO2I6SskDqxlL8vvEZ33t9z5yL0CtjszRIVECcVAhhUieEqzQm8EaUPMsTLr1uwWg_2f3E9o7j45VWX560r-S4V5xPesX4xHMrpxPVb3li_YPRIAthnAVpf6pt_zq6AWM2SlcS9VNfX2McgvN2spxndBk32dDNPo-inm9R69rWUAggIC2K1_ySl-9fc0__hp-XWZQrbml4G31pDarZKGe9RSV76sclrccrWXwH3WqCVbxd73IXXTPFPbQ5asrx99HvQwMjweCTpvkI9nJQc2wBXOV3cIp4fjGZVqWXhcUt76vA7uMvPoSUmgzKzyTCHyeOFljgvNB4x5xXOf4GKbxj6MBB2Pf-MF3YooxrX4Lhrw3__Py1lxeA7wv3M3qNt_HMVLOynTnaxdNlazLiXLXuYrgNgKjGrinwrMJeWfcBOhq-PRrskqYpBFEsziqireUsl6GyAY21SWJNlYGsNNNBqsMw0RLAYKTiOmMmDlRieaxhEfJAxpbSh2ijKAvzGGGeKcriyFKTMmZCynNNIfxiJrCMQ5jYQaRFhJjW0h-i5cSdihpMwpkoajB10BsHm-W-TrjbryhnX0XzMIUThaY65kpH1pXSJYM1lOa5dvXkMOmgtAWdaGKgOraBU43_c_mXLUYFvCJc3ScvTLmYC4jBMqf6k8DZH9WYXd5kC3-47hqa16xY3wIY9TLkDSa3rnzkC7R5sDMUH97tv3-CbjpTag7eU7RRzRbmGUR7lXzux_VfdeRXaw
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Severe+hospital+events+following+symptomatic+infection+with+Sars-CoV-2+Omicron+and+Delta+variants+in+France%2C+December+2021%E2%80%93January+2022%3A+A+retrospective%2C+population-based%2C+matched+cohort+study&rft.jtitle=EClinicalMedicine&rft.au=Vincent+Auvigne&rft.au=Sophie+Vaux&rft.au=Yann+Le+Strat&rft.au=Justine+Schaeffer&rft.date=2022-06-01&rft.pub=Elsevier&rft.issn=2589-5370&rft.eissn=2589-5370&rft.volume=48&rft.spage=101455&rft_id=info:doi/10.1016%2Fj.eclinm.2022.101455&rft.externalDBID=DOA&rft.externalDocID=oai_doaj_org_article_62753d58cd2f4466b462733aad503316
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=2589-5370&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=2589-5370&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=2589-5370&client=summon